Arterial infusion chemo and dual immunotherapy for pancreatic cancer liver metastases
Part of Cancer, Digestive system clinical trials.
This trial tests a new first-line treatment for pancreatic cancer that has spread to the liver. It combines chemotherapy delivered directly to the liver's blood supply with two immunotherapy drugs to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread to the liver and hasn't been treated yet.
- You are between 18 and 75 years old.
- You are in good enough health to be up and about (ECOG score 0-1).
- Your tumor has a good blood supply, as seen on a special x-ray during a procedure.
- You have not had certain cancer treatments before, including immunotherapy drugs like PD-1 or CTLA-4 blockers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
Hear when a new Pancreatic Cancer Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.